Proactive’s Post

The groundbreaking impact of GLP-1 drugs on weight loss can't be overstated—the market is projected to soar to $100B by 2030! 📈 Wegovy, Ozempic, and other game-changers have transformed this landscape, and VettaFi's Weight Loss Drug & Treatment Index ($THINR) has seized the opportunity. Since its launch on 1/25/24, the index has surged 17.25% YTD, delivering impressive returns (as of 5/10/24). Now, investors can invest in this space with the launch of Amplify ETFs' $THNR. Amplify is a leader in innovative #investing solutions, and we're thrilled to support this #ETF, which tracks our index. Jane Edmondson delves into our index approach, industry background, and more in her latest piece: https://lnkd.in/gEHx7-gc #Index #Indexing #Indexation

See how #ActiveDisclosure helped Arcellx, a leading biotech company, save hours on their SEC filings & increase reporting productivity in DFIN's latest case study. Download the full case study: https://lnkd.in/eCGCfeji

$EVAX - Implied volatility is down to 0.0 for Evaxion Biotech: As of the 12th of January 2024, Evaxion Biotech shows the Semi Deviation of 7.95, downside deviation of 9.47, and Mean Deviation of 4.77. Evaxion Biotech AS technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to analyze nineteen technical drivers for Evaxion Biotech AS, which can be compared to its rivals. Please confirm Evaxion Biotech AS coefficient of variation, as well as the relationship between the treynor ratio and semi variance to decide if Evaxion Biotech AS is priced favorably, providing market reflects its regular price of 0.75 per share. As Evaxion Biotech AS is a penny stock we also recommend to verify its total risk alpha numbers. https://lnkd.in/g7fwUCcy

This is an interesting theme catching momentum, and the index industry and ETFs offer effective ways to access it. Lots of research into this from VettaFi - and a new product $THNR from Amplify ETFs.

Thinking about investing in a CTMS? Don't get surprised by hidden fees! SimpleTrials offers a transparent pricing model with all the features you need at an affordable cost. Click here to read our article and discover the true cost of a CTMS: https://buff.ly/3E3yz1e #sponsors #clinicaltrials #ctms #etmf #biotech

Shares in Futura Medical PLC (AIM:FUM, OTC:FAMDF) were up 36% in the first hour of trade following its 2023 trading statement, which covered its commercial progress and breakthrough in the US market. Largely historic, the update reminded investors that the group now has approval for its erectile dysfunction (ED) gel as an over-the-counter product in the States as well as a blue-chip partner in the form of Haleon PLC (LSE:HLN, NYSE:HLN). Investment bank Liberum, in a note to clients, said: "Aside from a little timing difference that has already reversed out, Futura is progressing in line with expectations and today’s trading update is a timely reminder of how much progress the company has made and how little credit it has been given for this progress." More at #Proactive #ProactiveInvestors #futuramedical #ED #eroxon http://ow.ly/GLOG105fqsJ

Discover optimal drug combinations for your lead compound using SynergyFinder™. Our platform quantitatively assesses synergy to guide your development strategy. Find out how: https://ow.ly/gscE50Ry6JC #Drugdiscovery #ddrugcombination #synergy

PharmAust Completes Successful Share Purchase Plan We are thrilled to announce the completion of our Share Purchase Plan (SPP), which raised an impressive $7.8 million, significantly exceeding our initial $2 million target. This strong demand reflects the exceptional support from our shareholders, who were offered the same terms as our recently completed $10 million institutional Placement. The combined $17.8 million from the SPP and Placement substantially strengthens our balance sheet and minimizes future funding needs as we advance the development of monepantel for ALS and other neurodegenerative conditions. Our Chairman, Sergio Duchini, extends his heartfelt gratitude to all shareholders for their unwavering support and confidence in PharmAust’s strategic direction. PharmAust Chairman Sergio Duchini commented: 'With these funds, we are well-positioned to commence the HEALEY ALS Platform Trial and achieve significant milestones in H2 CY2024. We look forward to keeping you updated on our progress." Thank you to all our shareholders for your continued support! #PharmAust #ASX #ALSResearch #NeurodegenerativeDiseases #Biotech #CapitalRaising #SharePurchasePlan

Dexcom Strategic Masterclass Dexcom received clearance for the first OTC glucose monitor in the US on Tuesday, but the interest part is the strategy behind it. Dexcom are the first major MedTech company to come out with a strategy to take advantage of the GLP1 surge rather than try to rationalize it away. Bravo Dexcom! #digitalhealth #strategy

Pitt Street Research just published an update note on Immuron. Earlier this month, the company revealed interim topline results from its Phase 2 trial in Travelan. The results were positive and bode well for the company to pursue a Phase 3 clinical trial. Although complete results are not due until later this year, the company will now proceed to hold an end of Phase 2 meeting with the FDA to discuss the pivotal Phase 3 registration strategy as well as explore funding for Phase 3. By merely entering Phase 3, Immuron will be among an exclusive list of ASX biotech stocks in Phase 3. We expect this fact alone to lead to continued growth momentum in the months ahead. We reiterate our valuation of Immuron as first outlined in our initiation report – at A$0.25 per share in a base case scenario and A$0.35 per share in an optimistic (bull) case scenario. Even with the recent re-rate following the results, it is well below the valuation of other ASX companies in Phase 3 and we expect the gap to close in the coming months as the company moves towards Phase 3. Please be advised that this report is General Advice only and is a report the company has commissioned Pitt Street to Prepare. Please see page 9 for the key risks and the final page for the full Disclosures, Disclaimer and General Advice Warning. #immuron #imm #gastrointestinalhealth #gastrointestinal #travelan #protectyn #stocks #equities #stockmarket #investing #investors #research #researchreport #researchinitiation #equityresearch Stuart Roberts Marc Kennis Steven Lydeamore Paul Brennan Roger Aston Jerry Kanellos